EZH2, the enzymatic component of PRC2 is mutated in myeloid malignancies, most commonly in MDS, chronic myelomonocytic leukemia (CMML), and primary myelofibrosis and rarely in AML (14–16). Here, EZH2 is linked to chronic myelomonocytic leukemia.